Browsing by Author "Yen, Shih-Chieh"

Now showing 1 - 3 of 3

Effectiveness of holographic optical element module sensor in measuring blood prothrombin time
(2014-07-01)
Lin, Yu-Cheng
;
Yen, Shih-Chieh
;
Cheng, Stone
;
Huang, Tony
;
機械工程學系
A small-form-factor holographic optical element (HOE) module, which was mounted on a dual-stage seesaw actuator, was utilized to evaluate blood coagulation in real time. The method involved assessing the decrease in transmitted light of the blood sample surface when the clotting is formed. The prothrombin time (PT) was measured by illumining and focusing a 635 nm laser beam onto the sample. As the fibrinogen turned into non-solute fibrin, the transmitted efficiency and total intensity of the reflected light from the reflector changed. A low-pass filter suppressed the noise in the coagulation-related transient response to yield accurate signals. Finally, the PT measurements were compared to those made classically using other optical sensors.
Effectiveness of holographic optical element module sensor in measuring blood prothrombin time
(2014-07-01)
Lin, Yu-Cheng
;
Yen, Shih-Chieh
;
Cheng, Stone
;
Huang, Tony
;
機械工程學系
A small-form-factor holographic optical element (HOE) module, which was mounted on a dual-stage seesaw actuator, was utilized to evaluate blood coagulation in real time. The method involved assessing the decrease in transmitted light of the blood sample surface when the clotting is formed. The prothrombin time (PT) was measured by illumining and focusing a 635 nm laser beam onto the sample. As the fibrinogen turned into non-solute fibrin, the transmitted efficiency and total intensity of the reflected light from the reflector changed. A low-pass filter suppressed the noise in the coagulation-related transient response to yield accurate signals. Finally, the PT measurements were compared to those made classically using other optical sensors.
Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer
(2014-01-08)
Lin, Wen-Hsing
;
Yeh, Teng-Kuang
;
Jiaang, Weir-Torn
;
Yen, Kuei-Jung
;
Chen, Chun-Hwa
Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML). Hence, pharmacologic inhibitors of FLT3 are of therapeutic potential for AML treatment. In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC(50) approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD+ AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD+ AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy. Our results suggest that BPR1J-340 may be further developed in the preclinical and clinical studies as therapeutics in AML treatments.